BeiGene Ltd.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2010-01-01
- Employees
- 10K
- Market Cap
- $22.1B
- Website
- http://www.beigene.com
Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors
- First Posted Date
- 2018-11-09
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 200
- Registration Number
- NCT03736889
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
🇨🇳The Affiliated Hospital of Military Medical Sciences, Beijing, Beijing, China
🇨🇳Guangdong Provincial Peoples Hospital, Guangzhou, Guangdong, China
A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2018-11-07
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 652
- Registration Number
- NCT03734016
- Locations
- 🇺🇸
Carti Cancer Center, Little Rock, Arkansas, United States
🇺🇸David Geffen School of Medicine At UCLA, Los Angeles, California, United States
🇺🇸Rocky Mountain Cancer Centers Boulder, Boulder, Colorado, United States
Treatment of Metastatic Castration-Resistant Prostate Cancer With Homologous Recombination Deficiency
- Conditions
- Interventions
- First Posted Date
- 2018-10-19
- Last Posted Date
- 2021-11-17
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 13
- Registration Number
- NCT03712930
- Locations
- 🇺🇸
University of Washington, Seattle, Washington, United States
🇦🇺Liverpool Hospital, Liverpool, New South Wales, Australia
🇺🇸University Cancer and Blood Center, Athens, Georgia, United States
A Phase 1b Study to Assess Sitravatinib in Combination With Tislelizumab in Participants With Advanced Solid Tumors
- First Posted Date
- 2018-09-11
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 216
- Registration Number
- NCT03666143
- Locations
- 🇦🇺
Icon Cancer Foundation, South Brisbane, Queensland, Australia
🇦🇺Austin Health, Heidelberg, Victoria, Australia
🇦🇺Linear Clinical Research, Nedlands, Western Australia, Australia
A Study Evaluating the Efficacy and Safety of Tislelizumab Versus Chemotherapy in Advanced Non-Squamous Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-09-10
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 334
- Registration Number
- NCT03663205
- Locations
- 🇨🇳
Daping Hospital, Third Military Medical University, Chongqing, Chongqing, China
🇨🇳Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
🇨🇳Yunnan Cancer Hospital, Kunming, Yunnan, China
The Study of BGB-283 in Chinese Subjects With Local Advanced or Metastatic Malignant Solid Tumor
- First Posted Date
- 2018-08-22
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 42
- Registration Number
- NCT03641586
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
A Study of Tislelizumab in Combination With Chemotherapy Versus Chemotherapy in Advanced Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-07-20
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 360
- Registration Number
- NCT03594747
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
🇨🇳Beijing Chest Hospital,Capital Medical University, Beijing, Beijing, China
🇨🇳Anhui Provincial Hospital, Hefei, Anhui, China
Efficacy and Safety of BGB-290 in the Treatment of Metastatic HER2-Negative Breast Cancer Patients With BRCA Mutation in China
- First Posted Date
- 2018-07-02
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 88
- Registration Number
- NCT03575065
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
🇨🇳Sun Yat Sen Memorial Hospital, Sun Yat Sen University (North), Guangzhou, Guangdong, China
🇨🇳Sun Yat Sen University Cancer Center, Guangzhou, Guangdong, China
A Pharmacokinetic Study to Assess Drug-drug Interaction Between Zanubrutinib and a Cocktail of Substrates in Healthy Subjects
- First Posted Date
- 2018-06-19
- Last Posted Date
- 2019-11-04
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 18
- Registration Number
- NCT03561298
- Locations
- 🇺🇸
Covance Clinical Research Unit, Daytona Beach, Florida, United States
BTK Inhibitor BGB-3111 in Chinese Participants With Diffuse Large B-Cell Lymphoma (Non-GCB) and Indolent Lymphoma (FL and MZL)
- Conditions
- Interventions
- First Posted Date
- 2018-05-11
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 41
- Registration Number
- NCT03520920
- Locations
- 🇨🇳
Tongji Hospital of Tongji Medical College Huazhong University of Science and Technology, Wuhan, Hubei, China
🇨🇳Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China
🇨🇳Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China